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B
reast magnetic resonance (MR) imaging increased 16-fold between 2000 and 2011, and screening indications account for an increasing number of examinations in recent years (1) (2) (3) . Compared with mammographic imaging, breast MR imaging achieves higher sensitivity but lower
Implications for Patient Care
n When an incidental extramammary finding on breast MR images is evaluated, the radiologist should carefully review the electronic medical record and previous imaging studies to determine the necessity of additional imaging evaluation.
n The breast radiologist should recommend additional clinical and/ or imaging evaluation for incompletely characterized (CT colonography reporting and data system [C-RADS] category E3) and potentially important (C-RADS category E4) extramammary findings on breast MR images because additional evaluation can identify clinically important disease without substantially increasing cost. n Because hepatic lesions were the most frequent indication for additional imaging, abdominal MR imaging constituted 55.3% ($20 657 of $37 355) of the additional costs related to further imaging evaluation and follow-up examinations.
Advances in Knowledge
n Additional imaging performed secondary to recommendations from radiologists for further evaluation and follow-up of incidental findings resulted in an additional cost of $16 for each breast MR imaging examination. 
Data Extraction
For each breast MR imaging, the following data were extracted from the electronic medical record: patient age, clinical indication for breast MR imaging, availability of previous breast MR imaging for comparison, current and/ or previous history of breast cancer or other malignancy, available clinical follow-up, results of any additional imaging work-up at our institution, and biopsy type and pathology, if applicable. For each examination, the Breast Imaging Reporting and Data System assessment was extracted from the imaging report with the final assessment assigned to the most actionable category.
Each breast MR imaging report was reviewed by a single author (B.L.N. or D.L.B.) to determine the number and type of extramammary findings. Each extramammary finding was categorized with a modified computed tomographic (CT) colonography reporting and data system (C-RADS) classification system adapted to extracolonic findings (10, 11) . Briefly, C-RADS category E1 was defined as normal examination results or anatomic variants. Category E2 was assigned to findings deemed clinically unimportant because no further work-up or assessment was indicated (eg, hepatic cyst). Category E3 findings were likely benign but incompletely characterized, so further work-up could be performed if indicated (eg, aortic ectasia). Category E4 was assigned to potentially important findings that required further work-up and communication to the referring physician (10, 11) . Authors assigned the initial categories while blinded to clinical outcomes. For findings initially assigned to C-RADS E3 and E4 categories, the electronic medical record and previous imaging studies were reviewed to determine if the E3 or E4 finding had been previously described. If previously described and evaluated, the finding was downgraded and assigned a final C-RADS E2 category. For any examination with more than one extramammary finding, the breast MR imaging was classified according to the most actionable C-RADS category (in descending order, E4-E1). The electronic medical record was reviewed for each patient with a category E3 or E4 designation for at least 2 years after the breast MR examination to assess the clinical relevance for each extramammary finding.
On the basis of Medicare reimbursements, the costs of further imaging evaluation and follow-up studies were estimated with the 2014 Medicare physician fee schedule (12) . All studies performed as a result of a recommendation for further imaging evaluation of an extramammary finding were included in the cost analysis. Follow-up imaging studies performed because of any additional imaging recommendations were also included in cost analyses (eg, a follow-up chest CT scan to monitor pulmonary nodules identified on the initial chest CT scan that was recommended for further evaluation of a mediastinal mass seen at breast MR imaging). The terminology for imaging studies performed for further evaluation versus follow-up was previously described (13) . The cost for each imaging study was estimated by using the global reimbursement amount based on the Outpatient Prospective Payment System. The national payment amount (with a carrier locality code of 0000000) was used to increase generalizability of results across geographic areas. For simplicity, any payments for associated codes for three-dimensional imaging were omitted, similar types of imaging studies were grouped (eg, all chest CT scans performed were assumed to be noncontrast enhanced), and multiple procedure payment reductions were not incorporated into analyses. Subsequent procedures (biopsies or fineneedle aspirations) were omitted from cost analyses because the Outpatient Prospective Payment System global payment amount for an image-guided fine-needle aspiration (Current Procedural Terminology number 10022) is not listed on the Medicare physician fee schedule.
Statistical Analyses
We tested for statistical significance by using x 2 statistics; P values less than .05 indicated statistical significance (Microsoft Excel; Microsoft Corporation, Redmond, Wash), and we calculated 95% exact confidence intervals (CIs). The only C-RADS category E1 finding described in a breast MR imaging report in our study was an aberrant right subclavian artery. Table 1 outlines the frequency of C-RADS E2, E3, and E4 findings in the remaining 390 patients. Of the 391 patients with extramammary incidental findings identified at breast MR imaging, 285 patients (72.9%) were designated as C-RADS E2 (Table 1) . In our study, a previously described finding was categorized as C-RADS E2. Of the 285 patients with a final assignment to the C-RADS E2 category, 133 patients (46.7%) were downgraded from an initial C-RADS category E3 or E4 on the basis of
Results

Extramammary Findings
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Note.-There were 319 category-E2 findings. NOS = not otherwise specified, STIR = short inversion time inversion recovery.
previous imaging results or review of the electronic medical record. Among the 319 findings categorized as C-RADS E2, the most common included hepatic masses (60.2% [192 of 319]) ( Table 2 ). Skeletal and skin lesions were the next most common benign findings. Among the 113 C-RADS E3 and E4 findings, the most common included hepatic hyperintense masses found by using a short inversion time inversion recovery sequence (49.6% [56 of 113]) that were incompletely characterized on the breast MR examination (Table 3) . Lung, pleural, or mediastinal abnormalities were the next most common extramammary findings, with each group representing 10.6% (12 of 113) of the C-RADS E3 and E4 findings.
Additional Imaging Recommendations
Of the 2324 breast MR examinations, 86 patients (3.7% [95% CI: 3.0%, 4.5%) had a recommendation for additional imaging to be performed for further evaluation of an extramammary finding. Of these 86 patients, 45 patients (52%) were evaluated as C-RADS category E3 and 38 patients (44%) were evaluated as E4. Three patients (3.5%) were assigned C-RADS category E2, which suggested that the recommendation for additional imaging was unnecessary. Of 1628 patients with screening indications for breast MR imaging, 45 patients (2. Nine of 2324 patients (0.4% [95% CI: 0.2%, 0.7%]) had a clinically important finding identified with breast MR imaging, and this included five patients (0.2% [95% CI: 0.1%, 0.5%]) who had previously unknown sites of metastatic disease or primary malignancy not in the breast. Two patients with a clinically important finding had a diagnostic indication for the breast MR imaging, and seven patients had screening indications. All five patients with an undiagnosed malignant lesion at the site of the extramammary finding had a previous or current history of cancer.
Costs of Additional Imaging Recommended on Breast MR Imaging
Of the 86 patients with recommendations for additional imaging, 83 patients had one additional imaging study recommended and three patients had two additional imaging studies recommended, which totaled 89 additional imaging studies that were recommended (Table 4) . Hepatic lesions accounted for 49% (44 of 89) of these recommendations, including 25 of the 29 recommendations for abdominal MR imaging with and without contrast agent, six of eight recommendations for abdominal ultrasonographic (US) imaging, and 13 recommendations for cross-sectional liver imaging. Hepatic lesions were also the most frequent indication for additional imaging examinations that were actually performed (Table 4) (Table 4 ). Subsequent imaging studies resulted in three CT-guided fine-needle aspirations of pulmonary nodules, one thyroid nodule fine-needle aspiration, and one US-guided core biopsy of a chest wall mass. These five procedures were excluded from the cost analyses. Table 4 tallies the global claims for all subsequent imaging studies actually performed as a result of a breast MR imaging recommendation for additional imaging evaluation. Global claims for all subsequent imaging studies performed totaled $37 355. Abdominal MR imaging, performed predominantly for further evaluation of hepatic lesions, constituted 55.3% ($20 657 of $37 355) of the additional costs (Table 4 ). The 2014 Center for Medicare and Medicaid Services global claim for a breast MR examination with and without contrast agent is $576 (Table 4) . Therefore, for each of the 2324 breast MR examinations performed in this study, an average additional cost of $16 was attributable to the additional imaging recommended.
Subanalyses of cost were performed for the 31 of 1310 incident screening breast MR examinations that resulted in recommendations for additional imaging evaluation. Abdominal MR imaging, performed predominantly for further evaluation of hepatic lesions, constituted 47.7% ($8506 of $17 832) of the additional costs. Global claims totaled $17 832 for all subsequent imaging studies that were performed. The 2014 Center for Medicare and Medicaid Services global claim for a breast MR imaging with and without contrast agent is $576. Therefore, for each of the 1310 incident screening breast MR imaging performed in this study, an average additional cost of $14 was attributable to the additional imaging recommended.
Discussion
In this study, we systematically reviewed incidental findings detected on consecutive breast MR examinations to determine the prevalence of extramammary findings, the frequency of clinically important incidental findings and their impact on patient outcomes, and the cost of additional imaging studies recommended for further evaluation and follow-up of the incidental findings. Approximately 17% of patients who underwent a breast MR examination had an extramammary incidental finding, and 4.5% of patients had an incidental finding for which clinical correlation or additional evaluation was warranted. Our findings are consistent with previous smaller studies (14, 15) of breast MR examinations that demonstrated that 10%-34% of patients have extramammary incidental findings and 4.6% of patients have an incidental finding that is clinically significant. Our findings are similar to results from other cross-sectional imaging examinations. The prevalence of clinically important incidental findings is 4%-10% for CT colonography, 4.3% in lumbar spine CT imaging, and 3.4% in body MR imaging of healthy control patients (10, 11, 16, 17) .
In our study, patients with diagnostic indications for breast MR imaging were significantly more likely to have a recommendation for additional imaging evaluation compared with patients with screening indications. Over the preceding several years, screening indications for breast MR imaging have outpaced diagnostic indications (1,2).
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Niell et al Therefore, in the future, the frequency of clinically relevant extramammary findings may decrease as the use of MR imaging for screening increases because an incidental extramammary finding would be expected to have a lower prior probability of malignancy in women who undergo breast MR imaging for screening rather than for diagnostic indications. Our study demonstrated that 0.2% of patients who underwent breast MR imaging had an incidental finding that represented an undiagnosed extramammary malignancy or unknown site of metastatic disease, similar to the 0.4% and 0.7% prevalence of cancers incidentally detected on CT colonography and cardiac CT imaging, respectively (16, 18, 19) . All patients with an undiagnosed malignant lesion at the site of the extramammary finding had a previous or current history of cancer. Therefore, breast radiologists should be aware of a previous or current history of malignancy, in addition to breast cancer, before interpretation of an examination.
Concern exists regarding the potential for increased use of imaging for further evaluation of incidental findings and the associated costs. This concern was cited in the 2009 Center for Medicare and Medicaid Services decision to not cover screening CT colonography (20, 21) . However, evaluation of the frequency of additional imaging recommendations without evaluation of the frequency of additional imaging examinations actually performed overestimates the self-referral contribution on the part of the radiologist to the volume of medical imaging (22) . In our study, only 3.7% of breast MR examinations resulted in a recommendation for imaging to further evaluate an extramammary incidental finding, and only 2.5% of breast MR examinations resulted in additional imaging examinations that were actually performed. Our results lend support to previously published data that only 1.1%-3.5% of initial MR examinations result in subsequent high cost imaging examinations (22) . It is therefore not surprising that additional imaging Table 4 Frequency (28) 17 (29) 29 (64) 46 (45) 71 250 178.04
8190 (22) Abdominal MR imaging with and without contrast agent 29 (33) 24 (41) 10 (22) 34 ( (13) . These white papers provide guidance to radiologists for the appropriate management of abdominal and pelvic incidental findings, and familiarity with these guidelines results in a decreased frequency of recommendations for additional imaging (13, 20, 25) . On breast MR imaging, hepatic lesions represent the majority of extramammary findings for which additional imaging evaluation is recommended (14, 15) . Therefore, breast radiologists should become familiar with the American College of Radiology white papers, especially for incidental liver lesions, and the American College of Radiology Appropriateness Criteria for the initial characterization of liver lesions (13, 20, 26) . For example, the American College of Radiology Appropriateness Criteria for the initial characterization of liver lesions states that subcentimeter "hepatic lesions are difficult to characterize, although MR imaging may be helpful. In patients with extrahepatic primary malignancy, these small lesions are often evaluated with follow-up imaging because most are benign" (26) . Our study has several limitations. Extramammary incidental findings were identified by review of breast MR imaging reports, rather than by reviewing the images, because of the large number of breast MR examinations in our study. This may have underestimated the prevalence of extramammary findings on breast MR imaging. However, the low frequency of further imaging that was recommended suggests that only a small number of the potentially missed extramammary findings would have undergone additional imaging evaluation. Retrospective C-RADS categorization is another limitation. To minimize potential bias, authors assigned the C-RADS categorization while blinded to clinical outcomes. There are also limitations regarding the analysis for reimbursements of subsequent imaging studies performed as a result of incidental extramammary findings. The analysis incorporated only imaging studies and did not include procedures, which underestimated the overall cost. Another limitation is that women who had additional imaging recommended on breast MR imaging might have undergone further evaluation outside of our institution, and those data would not be captured in our study.
In conclusion, 3.7% of breast MR examinations result in radiologist recommendations for additional imaging evaluation of an extramammary incidental finding. Additional imaging evaluation for incompletely characterized and potentially important extramammary findings on breast MR imaging can identify clinically important disease in 11.5% of patients in whom additional imaging was recommended, without substantially increasing cost.
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